Penny $0.8 costing shares from Regulus Therapeutics (NASDAQ: RGLS) suddenly jumped over 25% in premarket after the company announced that FDA has granted Orphan Drug Designation to RGLS4326 for the treatment of patients with ADPKD.
During the last months of 2014 and beginning of 2015 RGLS had a record high price due to good earnings and rising revenue. Poor financial results and less news regarding the development of new drugs have led the company to face penny stock for a while. Perhaps soon this situation may change drastically because of new scientists who can create breakthrough drugs to fight complicated diseases.
For gambling investors, RGLS could be a perfect stock to lose or win quickly based on speculation with good news from the research and development unit. Spending about $1000 might be a wise decision to experience uncertain change.